Historical record - last NADAC effective date: 6/19/2024
Product Information
BUTALBITAL-ACETAMINOPHEN 50-325 MG TAB is a generic product labeled by Larken Laboratories, Inc., priced at $0.7692 per EA under NDC 68047072130. Its NADAC has been published 277 times since Mar 6, 2019.
FDA first approved this application on Dec 4, 2015. Its Orange Book therapeutic-equivalence code is AA.
Strength
325; 50 mg/1; mg/1
Manufacturer
Larken Laboratories, Inc.NDC
68047072130
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
6/19/2024
Active Ingredients
ACETAMINOPHEN; BUTALBITALApproval Type
Generic (ANDA)
FDA Application
ANDA203484FDA Approved
12/4/2015
TE Code
AA
On Market Since
12/4/2015
Pharmacological Classes
Price Statistics
The NADAC for BUTALBITAL-ACETAMINOPHEN 50-325 MG TAB has been published 277 times since Mar 6, 2019, and over the history we have for it it has declined 35.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.7692 per EA |
|---|---|
| All-time high | $1.1927 (Mar 13, 2019) |
| All-time low | $0.5829 (Aug 23, 2023) |
| Median price | $0.9283 |
| Average price | $0.9231 |
| Largest weekly change | +47.5% (Sep 21, 2022) |
| Weeks tracked | 277 |
| Tracking since | Mar 6, 2019 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
-5.6%
5Y
+14.9%
All
-35.5%
Last surveyed Jun 19, 2024 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 26% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Larken Laboratories, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
butalbital and acetaminophen market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Barbiturate class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of BUTALBITAL-ACETAMINOPHEN 50-325 MG TAB?
The current National Average Drug Acquisition Cost (NADAC) for BUTALBITAL-ACETAMINOPHEN 50-325 MG TAB, manufactured by Larken Laboratories, Inc., is $0.7692 per EA (NDC 68047072130), effective Jun 19, 2024.
How has the price of BUTALBITAL-ACETAMINOPHEN 50-325 MG TAB changed over time?
Over the history we have for it, the NADAC for BUTALBITAL-ACETAMINOPHEN 50-325 MG TAB has declined 35.5%. It has been tracked across 277 weekly CMS publications since Mar 6, 2019.
What are the highest and lowest recorded NADAC prices for BUTALBITAL-ACETAMINOPHEN 50-325 MG TAB?
Since Mar 6, 2019, the NADAC for BUTALBITAL-ACETAMINOPHEN 50-325 MG TAB has ranged from a low of $0.5829 (Aug 23, 2023) to a high of $1.1927 (Mar 13, 2019), with a median of $0.9283 per EA.
Are there cheaper alternatives to BUTALBITAL-ACETAMINOPHEN 50-325 MG TAB?
Yes. 3 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, BUTALBITAL-ACETAMINOPHEN 50-325 MG TAB, is $0.5709 per EA — about 26% below BUTALBITAL-ACETAMINOPHEN 50-325 MG TAB.
Who manufactures BUTALBITAL-ACETAMINOPHEN 50-325 MG TAB?
BUTALBITAL-ACETAMINOPHEN 50-325 MG TAB (NDC 68047072130) is labeled by Larken Laboratories, Inc., and CMS classifies it as a generic product.